Conference Coverage

DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use



The dramatically positive safety and efficacy results from the DAPA-CKD trial, which showed that treatment with the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin significantly cut both chronic kidney disease progression and all-cause death in patients with or without type 2 diabetes, were also notable for broadening the population of patients eligible for this treatment to those in the upper range of stage 4 CKD.

Dr. Hiddo J.L. Heerspink, professor of clinical pharmacology, Groningen University, the Netherlands Courtesy European Society of Cardiology

Dr. Hiddo J.L. Heerspink

Of the 4,304 CKD patients enrolled in DAPA-CKD, 624 (14%) had an estimated glomerular filtration rate (eGFR) of 25-29 mL/min per 1.73m2, an unprecedented population to receive a drug from the SGLT2 inhibitor class in a reported study. The results provided definitive evidence for efficacy and safety in this range of renal function, said Hiddo J.L. Heerspink, Ph.D., at the virtual annual meeting of the European Association for the Study of Diabetes.

Until now, the widely accepted lowest level for starting an SGLT2 inhibitor in routine practice has been an eGFR as low as 30 mL/min per 1.73 m2.

Using SGLT2 inhibitors when eGFR is as low as 25

“It’s time to reduce the eGFR level for initiating an SGLT2 inhibitor to as low as 25,” said Dr. Heerspink, a professor of clinical pharmacology at the University of Groningen (the Netherlands).

While conceding that this is primarily a decision to be made by guideline writers and regulatory bodies, he declared what he believed was established by the DAPA-CKD findings: “We’ve shown that dapagliflozin can be safely used in these patients. It is effective across the spectrum of kidney function.”

Other experts not associated with the study agreed.

Dr. Chantal Mathieu is vice-president of the EASD.and a professor of medicine at the Katholieke Universiteit Leuven (Belgium) Sara Freeman/MDedge News

Dr. Chantal Mathieu

The trial researchers were “brave” to enroll patients with eGFRs as low as 25 mL/min per 1.73 m2, and “we urgently need these agents in patients with an eGFR this low,” commented Chantal Mathieu, MD, an endocrinologist and professor of medicine at Catholic University in Leuven, Belgium, and designated discussant for the report. Overall, she called the findings “spectacular,” a “landmark trial,” and a “winner.”

The study also set an new, lower floor for the level of albuminuria that can be usefully treated with dapagliflozin (Farxiga) by enrolling patients with a urinary albumin-to-creatinine ratio as low as 200 mg/g; the previous lower limit had been 300 mg/g, noted Dr. Mathieu. The new findings pose challenges to guideline writers, regulators who approve drug labels, and payers to a quickly make changes that will bring dapagliflozin to a wider number of patients with CKD.

Once the full DAPA-CKD results are reported, “it will change practice, and push the eGFR needle down” to as low as 25. It will also lower the albuminuria threshold for using dapagliflozin or other drugs in the class, commented David Z.I. Cherney, MD, a nephrologist at the University of Toronto. “It’s just one study,” he admitted, but the consistent renal benefits seen across several studies involving all four drugs in the SGLT2 inhibitor class will help hasten this change in identifying treatable patients, as well as expand the drug class to patients with CKD but no type 2 diabetes (T2D).

Dr. David Cherney director of the renal physiology laboratory at the University Health Network, Toronto, Canada

Dr. David Cherney

“I don’t think we’ve ever had stronger evidence” for drugs that can benefit both heart and renal function, plus the drug class is “very safe, and really easy to start” and maintain in patients, Dr. Cherney said in an interview. “It’s wonderful for these patients that we now have something new for treatment,” a drug with a “very favorable benefit-to-risk ratio.”


Recommended Reading

Hyperglycemia predicts COVID-19 death even without diabetes
The Hospitalist
Guidance addresses elders with diabetes during COVID-19
The Hospitalist
Cleaner data confirm severe COVID-19 link to diabetes, hypertension
The Hospitalist
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The Hospitalist
COVID-19 taking financial toll on people in U.S. with diabetes
The Hospitalist
Guidance covers glycemia in dexamethasone-treated COVID-19 patients
The Hospitalist
Does metformin reduce risk for death in COVID-19?
The Hospitalist
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
The Hospitalist
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
The Hospitalist
Gut bacteria linked to cardiovascular, other health conditions
The Hospitalist
   Comments ()